Sanofi shows how $500M bowel disease bet compares to Merck and Roche's rival assets
Sanofi has shared a deeper dive into its 469 million euro bowel disease bet, publishing phase 2 data that provide a clearer look at how the Teva-partnered prospect compares to Merck & Co. and Roche’s rival candidates.
Sanofi has shared a deeper dive into its 469 million euro bowel disease bet, publishing phase 2 data that provide a clearer look at how the Teva-partnered prospect compares to Merck & Co. and Roche’s rival candidates.
